Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers

Aleksandra V. Brodskaia, Alexander S. Timin, Andrey N. Gorshkov, Albert R. Muslimov, Andrei B. Bondarenko, Yana V. Tarakanchikova, Yana A. Zabrodskaya, Irina L. Baranovskaya, Eugenia V. Il'inskaja, Elena I. Sakhenberg, Gleb B. Sukhorukov, Andrey V. Vasin

Результат исследований: Материалы для журналаСтатья

2 Цитирования (Scopus)

Выдержка

In the present study, a highly effective carrier system has been developed for the delivery of antiviral siRNA mixtures. The developed hybrid microcarriers, made of biodegradable polymers and SiO2 nanostructures, more efficiently mediate cellular uptake of siRNA than commercially available liposome-based reagents and polyethyleneimine (PEI); they also demonstrate low in vitro toxicity and protection of siRNA from RNase degradation. A series of siRNA designs (targeting the most conserved regions of three influenza A virus (IAV) genes: NP, NS, and PA) were screened in vitro using RT-qPCR, ELISA analysis, and hemagglutination assay. Based on the results of screening, the three most effective siRNAs (PA-1630, NP-717, and NS-777) were selected for in situ encapsulation into hybrid microcarriers. It was revealed that pre-treatment of cells with a mixture of PA-1630, NP-717, and NS-777 siRNAs, delivered by hybrid microcarriers, provided stronger inhibition of viral M1 mRNA expression and control of NP protein level, after viral infection, than single pre-treatment by any of three encapsulated siRNAs used in the study. Moreover, the effective inhibition of replication in several IAV subtypes (H1N1, H1N1pdm, H5N2, and H7N9) using a cocktail of the three selected siRNAs, delivered by our hybrid capsules to the cells, was achieved. In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy.

Язык оригиналаАнглийский
Страницы (с-по)147-160
Число страниц14
ЖурналAntiviral Research
Том158
DOI
СостояниеОпубликовано - 1 окт 2018

Отпечаток

Influenza A virus
Small Interfering RNA
Genes
Polyethyleneimine
H1N1 Subtype Influenza A Virus
Nanostructures
Hemagglutination
Virus Diseases
Therapeutics
Ribonucleases
Liposomes
Human Influenza
Capsules
Antiviral Agents
Polymers
Enzyme-Linked Immunosorbent Assay
Technology
Messenger RNA
Proteins
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Цитировать

Brodskaia, A. V., Timin, A. S., Gorshkov, A. N., Muslimov, A. R., Bondarenko, A. B., Tarakanchikova, Y. V., ... Vasin, A. V. (2018). Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers. Antiviral Research, 158, 147-160. https://doi.org/10.1016/j.antiviral.2018.08.003

Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers. / Brodskaia, Aleksandra V.; Timin, Alexander S.; Gorshkov, Andrey N.; Muslimov, Albert R.; Bondarenko, Andrei B.; Tarakanchikova, Yana V.; Zabrodskaya, Yana A.; Baranovskaya, Irina L.; Il'inskaja, Eugenia V.; Sakhenberg, Elena I.; Sukhorukov, Gleb B.; Vasin, Andrey V.

В: Antiviral Research, Том 158, 01.10.2018, стр. 147-160.

Результат исследований: Материалы для журналаСтатья

Brodskaia, AV, Timin, AS, Gorshkov, AN, Muslimov, AR, Bondarenko, AB, Tarakanchikova, YV, Zabrodskaya, YA, Baranovskaya, IL, Il'inskaja, EV, Sakhenberg, EI, Sukhorukov, GB & Vasin, AV 2018, 'Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers', Antiviral Research, том. 158, стр. 147-160. https://doi.org/10.1016/j.antiviral.2018.08.003
Brodskaia, Aleksandra V. ; Timin, Alexander S. ; Gorshkov, Andrey N. ; Muslimov, Albert R. ; Bondarenko, Andrei B. ; Tarakanchikova, Yana V. ; Zabrodskaya, Yana A. ; Baranovskaya, Irina L. ; Il'inskaja, Eugenia V. ; Sakhenberg, Elena I. ; Sukhorukov, Gleb B. ; Vasin, Andrey V. / Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers. В: Antiviral Research. 2018 ; Том 158. стр. 147-160.
@article{44bf6d6e48a94777a7bb497764954730,
title = "Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers",
abstract = "In the present study, a highly effective carrier system has been developed for the delivery of antiviral siRNA mixtures. The developed hybrid microcarriers, made of biodegradable polymers and SiO2 nanostructures, more efficiently mediate cellular uptake of siRNA than commercially available liposome-based reagents and polyethyleneimine (PEI); they also demonstrate low in vitro toxicity and protection of siRNA from RNase degradation. A series of siRNA designs (targeting the most conserved regions of three influenza A virus (IAV) genes: NP, NS, and PA) were screened in vitro using RT-qPCR, ELISA analysis, and hemagglutination assay. Based on the results of screening, the three most effective siRNAs (PA-1630, NP-717, and NS-777) were selected for in situ encapsulation into hybrid microcarriers. It was revealed that pre-treatment of cells with a mixture of PA-1630, NP-717, and NS-777 siRNAs, delivered by hybrid microcarriers, provided stronger inhibition of viral M1 mRNA expression and control of NP protein level, after viral infection, than single pre-treatment by any of three encapsulated siRNAs used in the study. Moreover, the effective inhibition of replication in several IAV subtypes (H1N1, H1N1pdm, H5N2, and H7N9) using a cocktail of the three selected siRNAs, delivered by our hybrid capsules to the cells, was achieved. In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy.",
keywords = "Hybrid microcontainers, Influenza A virus, RNAi therapy, siRNA delivery",
author = "Brodskaia, {Aleksandra V.} and Timin, {Alexander S.} and Gorshkov, {Andrey N.} and Muslimov, {Albert R.} and Bondarenko, {Andrei B.} and Tarakanchikova, {Yana V.} and Zabrodskaya, {Yana A.} and Baranovskaya, {Irina L.} and Il'inskaja, {Eugenia V.} and Sakhenberg, {Elena I.} and Sukhorukov, {Gleb B.} and Vasin, {Andrey V.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.antiviral.2018.08.003",
language = "English",
volume = "158",
pages = "147--160",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers

AU - Brodskaia, Aleksandra V.

AU - Timin, Alexander S.

AU - Gorshkov, Andrey N.

AU - Muslimov, Albert R.

AU - Bondarenko, Andrei B.

AU - Tarakanchikova, Yana V.

AU - Zabrodskaya, Yana A.

AU - Baranovskaya, Irina L.

AU - Il'inskaja, Eugenia V.

AU - Sakhenberg, Elena I.

AU - Sukhorukov, Gleb B.

AU - Vasin, Andrey V.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - In the present study, a highly effective carrier system has been developed for the delivery of antiviral siRNA mixtures. The developed hybrid microcarriers, made of biodegradable polymers and SiO2 nanostructures, more efficiently mediate cellular uptake of siRNA than commercially available liposome-based reagents and polyethyleneimine (PEI); they also demonstrate low in vitro toxicity and protection of siRNA from RNase degradation. A series of siRNA designs (targeting the most conserved regions of three influenza A virus (IAV) genes: NP, NS, and PA) were screened in vitro using RT-qPCR, ELISA analysis, and hemagglutination assay. Based on the results of screening, the three most effective siRNAs (PA-1630, NP-717, and NS-777) were selected for in situ encapsulation into hybrid microcarriers. It was revealed that pre-treatment of cells with a mixture of PA-1630, NP-717, and NS-777 siRNAs, delivered by hybrid microcarriers, provided stronger inhibition of viral M1 mRNA expression and control of NP protein level, after viral infection, than single pre-treatment by any of three encapsulated siRNAs used in the study. Moreover, the effective inhibition of replication in several IAV subtypes (H1N1, H1N1pdm, H5N2, and H7N9) using a cocktail of the three selected siRNAs, delivered by our hybrid capsules to the cells, was achieved. In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy.

AB - In the present study, a highly effective carrier system has been developed for the delivery of antiviral siRNA mixtures. The developed hybrid microcarriers, made of biodegradable polymers and SiO2 nanostructures, more efficiently mediate cellular uptake of siRNA than commercially available liposome-based reagents and polyethyleneimine (PEI); they also demonstrate low in vitro toxicity and protection of siRNA from RNase degradation. A series of siRNA designs (targeting the most conserved regions of three influenza A virus (IAV) genes: NP, NS, and PA) were screened in vitro using RT-qPCR, ELISA analysis, and hemagglutination assay. Based on the results of screening, the three most effective siRNAs (PA-1630, NP-717, and NS-777) were selected for in situ encapsulation into hybrid microcarriers. It was revealed that pre-treatment of cells with a mixture of PA-1630, NP-717, and NS-777 siRNAs, delivered by hybrid microcarriers, provided stronger inhibition of viral M1 mRNA expression and control of NP protein level, after viral infection, than single pre-treatment by any of three encapsulated siRNAs used in the study. Moreover, the effective inhibition of replication in several IAV subtypes (H1N1, H1N1pdm, H5N2, and H7N9) using a cocktail of the three selected siRNAs, delivered by our hybrid capsules to the cells, was achieved. In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy.

KW - Hybrid microcontainers

KW - Influenza A virus

KW - RNAi therapy

KW - siRNA delivery

UR - http://www.scopus.com/inward/record.url?scp=85051969568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051969568&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2018.08.003

DO - 10.1016/j.antiviral.2018.08.003

M3 - Article

AN - SCOPUS:85051969568

VL - 158

SP - 147

EP - 160

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -